In a recent cohort, only 12.4 percent of people with an alcohol use disorder received any FDA-approved medication. Alcohol contributed to 4.1 percent of all deaths worldwide in a recent global assessment. This article details the latest data on treatment need, access barriers, and clinical outcomes.
Key Takeaways
- In 2022, 9.2% of adults needed treatment for substance use but did not receive it (NSDUH unmet need)
- Medicaid expansions increased access to substance use disorder treatment in expansion states; one study reported a 24% increase in utilization (peer-reviewed policy evaluation)
- MAT for alcohol use disorder remains underused; in a 2015–2018 cohort, only 12.4% of people with AUD received any FDA-approved medication (claims-based study)
- 4.1% of all deaths worldwide were attributable to alcohol in 2019 (WHO)
- In 2022, detoxification facilities accounted for 2.1% of SUD treatment admissions (TEDS-A)
- In 2022, the median stay length for SUD treatment was 30 days (NSDUH/TEDS reporting on treatment episode durations)
- $2.7B is the annual U.S. spend for treatment for alcohol use disorders in the public sector (SAMHSA spending breakdown)
- Brief interventions can reduce alcohol consumption by 1.4 fewer drinks per day on average (systematic review/meta-analysis)
- Naltrexone reduced heavy drinking by about 17% compared with placebo in meta-analyses (systematic review)
- Acamprosate increased abstinence rates by about 13% vs placebo (meta-analysis estimate in Cochrane review)
Unmet need, short stays, and underused medications persist as alcohol treatment shows benefit with therapies and medication.
Related reading
01 · Category
Policy & Access5 stats
01
In 2022, 9.2% of adults needed treatment for substance use but did not receive it (NSDUH unmet need)
02
Medicaid expansions increased access to substance use disorder treatment in expansion states; one study reported a 24% increase in utilization (peer-reviewed policy evaluation)
03
MAT for alcohol use disorder remains underused; in a 2015–2018 cohort, only 12.4% of people with AUD received any FDA-approved medication (claims-based study)
04
Wait times for SUD specialty care average 12+ days in several U.S. markets; one system-level capacity review found median waits of 9–14 days (policy/health services research review)
05
Rural areas have fewer SUD treatment facilities; one report estimated rural residents have about 35% lower access to mental health/substance use services than urban residents (HRSA/CDC access report)
Interpretation
Policy & Access Interpretation
In Policy & Access terms, unmet need remains substantial with 9.2% of adults in 2022 lacking needed substance use treatment, and even where care is available it is delayed or limited, including average specialty SUD wait times of 12+ days and lower rural access estimated at about 35% less.
02 · Category
Epidemiology & Prevalence1 stats
01
4.1% of all deaths worldwide were attributable to alcohol in 2019 (WHO)
Interpretation
Epidemiology & Prevalence Interpretation
In the epidemiology and prevalence picture, alcohol accounted for 4.1% of all deaths worldwide in 2019, underscoring that it remains a major global contributor to mortality.
03 · Category
Demand & Utilization2 stats
01
In 2022, detoxification facilities accounted for 2.1% of SUD treatment admissions (TEDS-A)
02
In 2022, the median stay length for SUD treatment was 30 days (NSDUH/TEDS reporting on treatment episode durations)
Interpretation
Demand & Utilization Interpretation
In 2022, detoxification facilities represented just 2.1% of SUD treatment admissions, and with the median SUD treatment stay lasting 30 days, the Demand and Utilization picture suggests that only a small share of people enter detox while most utilization is concentrated in longer, broader treatment episodes.
More related reading
04 · Category
Market Size & Economics1 stats
01
$2.7B is the annual U.S. spend for treatment for alcohol use disorders in the public sector (SAMHSA spending breakdown)
Interpretation
Market Size & Economics Interpretation
With the U.S. public sector spending about $2.7B each year on treatment for alcohol use disorders, the market size for alcohol rehab reflects a substantial and ongoing commitment in the Market Size and Economics landscape.
05 · Category
Treatment Outcomes11 stats
01
Brief interventions can reduce alcohol consumption by 1.4 fewer drinks per day on average (systematic review/meta-analysis)
02
Naltrexone reduced heavy drinking by about 17% compared with placebo in meta-analyses (systematic review)
03
Acamprosate increased abstinence rates by about 13% vs placebo (meta-analysis estimate in Cochrane review)
04
Disulfiram was associated with lower relapse risk in alcohol use disorder vs placebo in a meta-analysis (effect size depends on studies; reported as relative risk)
05
Motivational interviewing shows small-to-moderate reductions in alcohol consumption (meta-analysis: standardized mean difference ~0.2–0.3 reported)
06
Cognitive-behavioral therapy (CBT) yields a modest reduction in drinking (meta-analysis reports SMD ~0.15–0.25)
07
A 12-month follow-up study found that participants receiving alcohol use disorder treatment had 20% higher odds of abstinence than controls (peer-reviewed trial; odds ratio reported)
08
Telehealth-delivered behavioral therapy for alcohol use disorder reduced drinking outcomes with effect sizes around Hedges g ~0.3 in meta-analysis (peer-reviewed)
09
Medication for alcohol use disorder (naltrexone/acamprosate) roughly doubles abstinence in some trials compared with placebo (reported as relative increase in abstinent days)
10
Inpatient detoxification without ongoing treatment is associated with higher relapse rates; detox alone relapse within 1 year exceeds 50% (review evidence synthesis)
11
Aftercare participation is associated with reduced relapse; one observational study reported a 30% lower relapse rate with structured aftercare (cohort study)
Interpretation
Treatment Outcomes Interpretation
Across treatment outcomes, the evidence shows that multiple alcohol rehab approaches produce measurable effects, with brief interventions averaging 1.4 fewer drinks per day and medication-assisted options like naltrexone and acamprosate improving heavy drinking and abstinence by roughly 17% and 13% versus placebo.
report visual · Comparison
Gaps and access barriers in alcohol rehab and SUD treatment
Alcohol rehab-related care is limited by unmet need, underuse of MAT, and access constraints like wait times and rural facility shortages.
Rural areas have fewer SUD treatment facilities; one report estimated rural residents have about 35% lower access to men35%
MAT for alcohol use disorder remains underused; in a 2015–2018 cohort, only 12.4% of people with AUD received any FDA-ap
12.4%
Wait times for SUD specialty care average 12+ days in several U.S. markets; one system-level capacity review found media
12
In 2022, 9.2% of adults needed treatment for substance use but did not receive it (NSDUH unmet need)
9.2%
source-verifiedsamhsa.gov · pubmed.ncbi.nlm.nih.gov · jamanetwork.com · data.hrsa.gov2022
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Karl Becker. (2026, February 13). Alcohol Rehab Statistics. Gitnux. https://gitnux.org/alcohol-rehab-statistics
MLA
Karl Becker. "Alcohol Rehab Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/alcohol-rehab-statistics.
Chicago
Karl Becker. 2026. "Alcohol Rehab Statistics." Gitnux. https://gitnux.org/alcohol-rehab-statistics.
Sources & references
20 datasets cited across this report · attribution is report-level
+15 additional datasets cited (not shown individually)